Navigation Links
XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
Date:12/13/2010

THOUSAND OAKS, Calif., Dec. 13, 3010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA™ (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the '147 study, demonstrated that XGEVA significantly improved median bone metastasis-free survival by 4.2 months (HR=0.85, 95 percent CI 0.73-0.98, p=0.03) compared to placebo (primary endpoint), and significantly improved time to first occurrence of bone metastases (secondary endpoint). Overall survival was similar between the XGEVA and placebo groups (secondary endpoint).

Overall rates of adverse events and serious adverse events were generally similar between XGEVA and placebo, with hypocalcemia and osteonecrosis of the jaw (ONJ) observed at increased frequencies in the XGEVA arm.  The yearly rate of ONJ in the XGEVA-treated group was similar to what has been observed in prior XGEVA trials.  

"Our data demonstrate that XGEVA, which antagonizes the RANK Ligand axis, limits the ability of tumors to colonize bone, an important finding for men at risk for bone metastases and their healthcare providers," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "We look forward to presenting these landmark data at an upcoming medical conference."

The RANK Ligand pathway, first discovered by Amgen scientists in the mid-1990s, is believed to play a central role in cancer-induced bone destruction, regardless of cancer type. Data suggest that in bone metastasis, the invasion of cancer is facilitated by bone destruction. Hence, increased bone resorption due to increased RANK Ligand expression appears to augment bone metastasis.

XGEVA is a fully human monoclonal antibody that binds to RANK Ligand, a protein essential for the formation, function and
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
2. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
3. Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
4. Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP
5. CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times
6. Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
7. Pre and Post-Operative Use of Caldolor® (Ibuprofen) Injection Significantly Reduces Pain and Opioid Use in Newly Published Study
8. Americans Confidence in Their Ability to Access and Pay for Healthcare Declines Significantly in May, According to Thomson Reuters Index
9. New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
10. Home Health Monitoring May Significantly Improve Blood Pressure Control, Kaiser Permanente Study Finds
11. Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- According to a new market research report ... Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite & Offsite), Consumables ... Forecast to 2020", published by MarketsandMarkets, The Sterilization Equipment Market ... at a CAGR of 7.6%.from 2015 to 2020. ... ables and 37 F ...
(Date:7/31/2015)... and SAN DIEGO , July 31, ... company Eisai Co., Ltd. (Headquarters: Tokyo ... and Halozyme Therapeutics, Inc. (Headquarters: San Diego, ... Torley , "NASDAQ: HALO") have signed a clinical collaboration ... ® , "eribulin") in combination with Halozyme,s investigational drug ...
(Date:7/30/2015)... 2015 Mettler-Toledo International Inc. (NYSE: MTD ... below are the highlights: , Sales in ... the prior year. Reported sales decreased 4% as currency ... , Net earnings per diluted share as reported (EPS) ... Adjusted EPS was $2.80 , an increase of ...
Breaking Medicine Technology:Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
(Date:8/3/2015)... ... August 03, 2015 , ... Constantin Vasilica, 48 from Romania wanted ... caused by diabetes after many years of suffering and using medications with strong side ... want to ask for extra time off or wait longer hours in the waiting ...
(Date:8/3/2015)... , ... August 03, 2015 ... ... a leading provider of medical information, risk management and investigative services, has ... and direction toward focused, expert information solutions that improve business outcomes for ...
(Date:8/3/2015)... ... August 03, 2015 , ... Recent reports by the American ... at least once in their lives. Often time, low back and sciatic pain can ... could only be managed clinically with powerful pain medication or spinal surgery. Dynamic ...
(Date:8/2/2015)... (PRWEB) , ... August 03, 2015 , ... For many “would be” entrepreneurs, starting ... get help” or “I can’t afford to start a business.” Neither needs be a major ... right and theoretical opportunity to start a business and be successful. The risks of starting ...
(Date:8/1/2015)... ... August 02, 2015 , ... AlignLife Office Coordinator Heather ... continuity of care for patients at this natural health care center in Winamac. , ... Mary Heal said. "Heather's role is vital to our approach because we want to ...
Breaking Medicine News(10 mins):Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:New Patient Advocate Enhances Natural Health Care 2
... help diagnose disease early, study shows, , TUESDAY, July ... fluid may accurately identify the people with mild cognitive ... a new study finds. , Changes in the chemistry ... of Alzheimer,s disease. If and when treatments are available ...
... ... programs included in prestigious national rankings , ... Indianapolis, IN (Vocus) July 21, 2009 -- Nine clinical programs ... the top 50 national programs in U.S. News & World Report,s "2009-10 America,s Best ...
... found on how they help arteries stay clear and healthy ... genetic technology, researchers have begun to discover the exact molecular ... spice -- and ordinary orange juice are good for the ... are reporting studies describing the range of genes that are ...
... - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com ... MEVAC-A for the country of Thailand. The registration is ... 2009. , This registration is required to accommodate a ... Mellow Hope products such as MEVAC-A, MEVAC-DTaP, and MEVAC-ACYW. ...
... (July 21, 2009) Columbia University Medical Center,s Jeffrey ... of schizophrenia, has been selected by the National Institute ... Health as principal investigator of a nationwide effort to ... experiencing a first episode of the psychotic symptoms of ...
... , MINNEAPOLIS, July 21 Providing a ... more productive workforce. However, without employee engagement, even the best wellness ... (NYSE Amex: FIT ) explores how Herbalife is motivating ... Life program. , , (Logo: ...
Cached Medicine News:Health News:Biomarkers May Predict Alzheimer's 2Health News:Biomarkers May Predict Alzheimer's 3Health News:Clarian Health/Indiana University School of Medicine Specialty Programs Ranked Among Best in Nation 2Health News:Clarian Health/Indiana University School of Medicine Specialty Programs Ranked Among Best in Nation 3Health News:Studies Show Genetic Activity of Antioxidants 2Health News:Studies Show Genetic Activity of Antioxidants 3Health News:Hard To Treat Diseases (HTDS.PK) Thailand Registration 2Health News:Columbia leads national effort to develop early intervention for schizophrenia 2Health News:Columbia leads national effort to develop early intervention for schizophrenia 3Health News:HealthFitness Helps Herbalife Engage Employees in Wellness Promotion Program Through Strategic Use of Incentives 2Health News:HealthFitness Helps Herbalife Engage Employees in Wellness Promotion Program Through Strategic Use of Incentives 3
The ENDO CLOSE™ trocar site closure device has application in laparoscopic procedures for approximation of tissues and percutaneous suturing for closing incision sites....
... of a 42" long suture inserted into a ... one end and scored on the other. The ... to a ST-3 needle. The opposite end of ... of the plastic tube. The scored end acts ...
... long ligature inserted into a plastic tube. The plastic ... the other. The suture protrudes from the narrow end ... knot which becomes secure after the device is activated. ... the scored end of the plastic tube. The scored ...
... consists of 18'' long ligature inserted into a plastic ... and scored on the other. The suture protrudes from ... loop with a knot which becomes secure after the ... is fastened to the scored end of the plastic ...
Medicine Products: